Wee1 inhibition potentiates Wip1-dependent p53-negative tumor cell death during chemotherapy

Chemotherapy-induced peripheral neuropathy: Current status and progress

(2016) Jamie R. Brewer et al.   GYNECOLOGIC ONCOLOGY

Exploring Different Strategies for Efficient Delivery of Colorectal Cancer Therapy

(2015) Congcong Lin et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Phase I Study of Single-Agent AZD1775 (MK-1775), a Wee1 Kinase Inhibitor, in Patients With Refractory Solid Tumors

(2015) Khanh Do et al.   JOURNAL OF CLINICAL ONCOLOGY

WIP1 Phosphatase as a Potential Therapeutic Target in Neuroblastoma

(2015) Mark Richter et al.   PLoS One

Lysine-specific modifications of p53: a matter of life and death?

(2015) Diana Marouco et al.   Oncotarget

Wee-1 Kinase Inhibition Overcomes Cisplatin Resistance Associated with High-Risk TP53 Mutations in Head and Neck Cancer through Mitotic Arrest Followed by Senescence

(2014) A. A. Osman et al.   MOLECULAR CANCER THERAPEUTICS

The γH2AX Assay for Genotoxic and Nongenotoxic Agents: Comparison of H2AX Phosphorylation with Cell Death Response

(2014) Teodora Nikolova et al.   TOXICOLOGICAL SCIENCES

Pathophysiology of Cisplatin-Induced Acute Kidney Injury

(2014) Abdullah Ozkok et al.   Biomed Research International

Chemotherapy induced DNA damage response

(2013) Derek Woods et al.   CANCER BIOLOGY & THERAPY

Preclinical Evaluation of the WEE1 Inhibitor MK-1775 as Single-Agent Anticancer Therapy

(2013) A. D. Guertin et al.   MOLECULAR CANCER THERAPEUTICS

WIP1, a Homeostatic Regulator of the DNA Damage Response, Is Targeted by HIPK2 for Phosphorylation and Degradation

(2013) Dong Wook Choi et al.   MOLECULAR CELL

miR-16 and miR-26a target checkpoint kinases Wee1 and Chk1 in response to p53 activation by genotoxic stress

(2013) L Lezina et al.   Cell Death & Disease

Cisplatin Sensitivity Mediated by WEE1 and CHK1 Is Mediated by miR-155 and the miR-15 Family

(2012) L. M. Pouliot et al.   CANCER RESEARCH

Wip1 sensitizes p53-negative tumors to apoptosis by regulating the Bax/Bcl-xLratio

(2012) Anastasia R. Goloudina et al.   CELL CYCLE

Role of Gadd45a in Wip1-dependent regulation of intestinal tumorigenesis

(2012) O N Demidov et al.   CELL DEATH AND DIFFERENTIATION

WEE1 Kinase Targeting Combined with DNA-Damaging Cancer Therapy Catalyzes Mitotic Catastrophe

(2011) P. C. De Witt Hamer et al.   CLINICAL CANCER RESEARCH

A Simple Protocol for Using a LDH-Based Cytotoxicity Assay to Assess the Effects of Death and Growth Inhibition at the Same Time

(2011) Shilo M. Smith et al.   PLoS One

Wip1 promotes RUNX2-dependent apoptosis in p53-negative tumors and protects normal tissues during treatment with anticancer agents

(2011) A. R. Goloudina et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Wip1 Directly Dephosphorylates  -H2AX and Attenuates the DNA Damage Response

(2010) H. Cha et al.   CANCER RESEARCH

Dephosphorylation of γ-H2AX by WIP1: An important homeostatic regulatory event in DNA repair and cell cycle control

(2010) Sung-Hwan Moon et al.   CELL CYCLE

UV-induced histone H2AX phosphorylation and DNA damage related proteins accumulate and persist in nucleotide excision repair-deficient XP-B cells

(2010) Kyu-Seon Oh et al.   DNA REPAIR

Synthetic lethality: General principles, utility and detection using genetic screens in human cells

(2010) Sebastian M.B. Nijman   FEBS LETTERS

Wild-type p53-induced Phosphatase 1 Dephosphorylates Histone Variant γ-H2AX and Suppresses DNA Double Strand Break Repair

(2010) Sung-Hwan Moon et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

TP53Mutations and Pathologic Complete Response to Neoadjuvant Cisplatin and Fluorouracil Chemotherapy in Resected Oral Cavity Squamous Cell Carcinoma

(2010) Federica Perrone et al.   JOURNAL OF CLINICAL ONCOLOGY

p38MAPK Controls Expression of Multiple Cell Cycle Inhibitors and Islet Proliferation with Advancing Age

(2009) Esther Sook Miin Wong et al.   DEVELOPMENTAL CELL

Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents

(2009) H. Hirai et al.   MOLECULAR CANCER THERAPEUTICS